Implementation of Patient Protection and Affordable Care Act of 2010 (Pub. L. 111-148); Health Care & Education Reconciliation
Act of 2010 (Pub. L. 111-152), Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub.L. 112-144), S. 957, Drug Supply Chain Security Act; H.R. 1919 the Safeguarding America's Pharmaceuticals Act of 2013, S. 959, Pharmaceutical Compounding Quality and Accountability Act,H.R. 3742, Antibiotic Development to Advance Patient Treatment (ADAPT) Act, Health care reform implementation; the 340B program of the Health Resources & Services Administration (HRSA), specifically 340B drug pricing issues, including program expansion and specific issues include: HRSA oversight, definition of patient, the ACA's expansion of covered 340B entities.
Ongoing discussions surrounding next steps for protecting and promoting incentives for the development of resistant pathogens
including breakpoints; antibiotic resistance among elderly population; issues related to 340B Drug Pricing Program; reimbursement issues for antibiotics. Issues related to Medicare reimbursement of antibiotics; S. 2000 / H.R. 4015, The SGR Repeal & Medicare Provider Payment
Modernization Act of 2014; H.R. 4302, Protecting Access to Medicare Act of 2014 and Public Law No. 113-93, and potential Medicare offsets that might be applied to prescription drugs in all issues listed. FY 2014 Omnibus HR 3547, FY 2014 Continuing Resolution H J Res 106 PL 113-73 and H J Res 59 PL 113-67, and potential Medicare offsets that might be applied to prescription drugs in all of the issues listed. Implementation of the Generating Antibiotics Incentives Now (GAIN) Act provisions/Title VIII of the Food & Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation, HR 3742 - the Antibiotic Development to Advance Patient Treatment of 2013, and HR 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014
HCR - Health Issues MMM - Medicare/Medicaid BUD - Budget/Appropriations PHA - Pharmacy
2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
CUBIST PHARMACEUTICALS, INC.
65 Hayden Avenue, Lexington, MA, 02421, US
MARK THOMAS BATTAGLINI GINETTE ELISE RHODES MARK THOMAS BATTAGLINI GINETTE ELISE RHODES MARK THOMAS BATTAGLINI GINETTE ELISE RHODES MARK THOMAS BATTAGLINI GINETTE ELISE RHODES